Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of Lenzilumab in Subjects With Previously Treated Chronic Myelomonocytic Leukemia (CMML)

NCT02546284 is registered in ClinicalTrials.gov with Humanigen, Inc. as lead sponsor.

NCT NCT02546284
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02546284 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of Lenzilumab in Subjects With Previously Treated Chronic Myelomonocytic Leukemia (CMML)
Lead sponsor
Humanigen, Inc.
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2016
Completion date
February 29, 2020
Enrollment
15 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myelomonocytic leukemia (cmml)